Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease

The main purpose of this study was to assess whether pharmacological treatments prescribed by respiratory physicians to patients with chronic obstructive pulmonary disease (COPD) were consistent with the guidelines. The treatments prescribed by respiratory physicians to 631 consecutive patients with COPD, compared to 879 asthmatics were prospectively recorded. All subjects underwent peak expiratory flow rate measurement, spirometry and assessment of recent evolution and dyspnoea (visual analogue and Medical Research Council scales). Patients with COPD received more treatments than asthmatics (mean±sd: 2.6±0.5 versus 2.2±0.4, p<0.0001). Treatments administered to patients with COPD were β2-agonists in 78% (versus 94% in asthmatics), anticholinergic agents (AC) in 56% (versus 16% in asthma), methylxanthines in 31% (versus 15% in asthma) and inhaled corticosteroids in 76% (versus 85% in asthma). Intensity of treatment was influenced by disease severity for all treatments except AC. In conclusion, pharmacological treatment of chronic obstructive pulmonary disease by respiratory physicians is only partially consistent with current guidelines, with a high proportion of inhaled corticosteroid prescriptions and a relative under-use of anticholinergic agents; this most likely reflects the persistent uncertainties of physicians, and emphasizes that more efforts are required to improve implementation of chronic obstructive pulmonary disease guidelines and assess the efficacy and cost-effectiveness of recommended strategies.

[1]  A. Buist.  Guidelines for the management of chronic obstructive pulmonary disease. , 2002, Respiratory medicine.

[2]  M. Miravitlles.  Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[3]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[4]  M. Miravitlles,et al.  Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. , 2000, Chest.

[5]  D. Stempel.  Montelukast added to inhaled beclomethasone in treatment of asthma. , 2000, American journal of respiratory and critical care medicine.

[6]  M. Cabana,et al.  Barriers pediatricians face when using asthma practice guidelines. , 2000, Archives of pediatrics & adolescent medicine.

[7]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[8]  M. Rudolf.  The reality of drug use in COPD: the European perspective. , 2000, Chest.

[9]  N Freemantle,et al.  Printed educational materials: effects on professional practice and health care outcomes. , 2000, The Cochrane database of systematic reviews.

[10]  Rian,et al.  A COMPARISON OF LOW-DOSE INHALED BUDESONIDE PLUS THEOPHYLLINE AND HIGH-DOSE INHALED BUDESONIDE FOR MODERATE ASTHMA , 2000 .

[11]  M. Laviolette,et al.  Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. , 1999, American journal of respiratory and critical care medicine.

[12]  N. Freemantle,et al.  Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? , 1999, JAMA.

[13]  P. Jones,et al.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.

[14]  M. Miravitlles,et al.  Tratamiento de la bronquitis crónica y la EPOC en atención primaria , 1999 .

[15]  J. Wilson,et al.  Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. , 1999, Chest.

[16]  M. Artés,et al.  Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. , 1999, Respiratory medicine.

[17]  S. Menjoge,et al.  Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. , 1999, Chest.

[18]  S. Campbell,et al.  For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. , 1999, Archives of internal medicine.

[19]  D. Postma,et al.  Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis , 1999, Thorax.

[20]  N. Gross,et al.  Inhalation by Nebulization of Albuterol-Ipratropium Combination (Dey Combination) Is Superior to Either Agent Alone in the Treatment of Chronic Obstructive Pulmonary Disease , 1998, Respiration.

[21]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[22]  Dave Davis,et al.  Does CME Work? An Analysis of the Effect of Educational Activities on Physician Performance or Health Care Outcomes , 1998, International journal of psychiatry in medicine.

[23]  A. Taylor-Vaisey,et al.  Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  P. Jones,et al.  Quality of life changes in COPD patients treated with salmeterol. , 1997, American journal of respiratory and critical care medicine.

[25]  D. Joyce,et al.  Prehospitalization inhaled corticosteroid use in patients with COPD or asthma. , 1997, Chest.

[26]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[27]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[28]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[29]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[30]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[31]  D. Mahler,et al.  Clinical evaluation of exertional dyspnea. , 1994, Clinics in chest medicine.

[32]  S. Anderson,et al.  Airway responsiveness : standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults , 1993 .

[33]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[34]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[35]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[36]  A. Buist.  Standardization of spirometry. , 1987, The American review of respiratory disease.